Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. She is currently on leave.
More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero � all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

ADHD Sufferers Are the Latest Casualties in the War on Drugs

By Megan McArdle
May 10 2011, 1:46 PM ET Comment

Apparently, there is a shortage of certain ADHD drugs in states stretching from the Mid-Atlantic to the Pacific Northwest.  A spokesman for the Hyperactivity Disorder Support Network notes that "This poses a serious risk for people with attention deficit problems, who may find it difficult to engage in normal life activities without their--ooh, nice tie!"


When I started to read the article, I had naturally assumed that this might have something to do with Pharma's supply chain problems.  And so it is--but in this case, the kink in the supply chain is the DEA:

Matt Cabrey, spokesman for Shire PLC, the maker of Adderall and generic versions, said rising demand for the drugs due to increased diagnoses of ADHD, which in turn may be fueled by greater awareness of the disorder, can make it difficult to forecast ingredient needs. But the current shortage, Mr. Cabrey said, is due to a delay last year at the U.S. Drug Enforcement Administration in releasing extra supplies of the drug's active ingredients. He said increased supplies are expected this month.

Because of the potential for abuse, the DEA regulates the active ingredients of some ADHD drugs as controlled substances. DEA spokesman Lawrence Payne said the agency has approved enough supply to allow for uninterrupted distribution of the drugs and it's up to manufacturers to allocate the ingredients among their various products.

Perhaps all our drug regulations are doing an absolutely splendid job of keeping Americans from suffering crippling drug addictions.  On the other hand, it's worth looking at the side effects.  Like the people suffering from chronic pain, who are often undertreated because the DEA prosecutes doctors unless they err on the side of assuming that a patient is faking pain to get drugs.  The cold and allergy sufferers who go without relief for their congestion because we've made it harder and harder to get pseudoephedrine.  The people who are killed in drug raids.  And now, apparently, the inability to get adequate supplies of common medications because the DEA controls the precursors, and is more willing to risk people going without their meds, than letting drug addicts get their hands on a slightly more convenient supply.

How far does all this have to ratchet before we say enough?  Preventing addiction is a worthy goal--but it's increasingly getting in the way of even more worthy goals, like making sure people have access to the medication that lets them live normal lives.


Presented by

More at The Atlantic

Silicon Valley's Next Big Thing: Beer Silicon Valley's Next Big Thing: Beer
Fact-Checking Claims on the Wonders of Pomegranate Juice Fact-Checking Claims on the Wonders of Pomegranate Juice
How the Global Middle Class Can Save the American Middle Class How the Global Middle Class Can Save America's Middle Class
'Men in Black 3': A Could-See 'Men in Black 3': A Could-See
'Tis the Season to be Hateful (in Sports) It's Okay to Hate Sports Stars

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
View All Correspondents

The Biggest Story in Photos

Where in the World? Part 3: A Google Earth Puzzle

May 25, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why You Can’t Get a Taxi

And how an upstart company may change that

Europe’s Real Crisis

The Continent’s problems are as much demographic as financial. They won’t go away soon.

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…